According to EP Pharma, the number of drugs approved by FDA in 2013 should end near 34 which would be fewer than last year's high of 43. But, significantly, the 2013 crop is projected to be worth more in peak sales figures at 5 years --- $18.7 B for 2013 versus $16.4 B for the 2012 cohort.
This will be largely due to introduction of drugs like Biogen Idec's $2.9 B blockbuster Tecfidera for MS and the assumed approval of Gilead's oral hepatitis C drug, sofosbuvir, $3B projected peak. The two drugs will account for nearly 32% of the total revenue from the 2013 class if things go as projected.
"Barring any upsets this will make 2013 a year to remember in terms of future blockbuster sales," said Lisa Urquhart, EP Vantage editor. See Fierce Biotech.